Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia

Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia --- a Double Blind Randomized Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01917045

Enrollment

180

Registered

2013-08-06

Start date

2012-01-31

Completion date

2013-03-31

Last updated

2013-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Pain Management

Keywords

sufentanil, morphine, postoperative pain control, body fat percentage, gynecology laparoscopic surgery, lipid solubility

Brief summary

The investigators noticed that Body Fat Ratio might have great influence on the efficacy of different lipid soluble anesthetics. The objective of this clinical trial was to compare the effect of that Body Fat Ratio on the efficacy of different lipid soluble anesthetics.

Detailed description

The objective of this clinical trial was to compare the effect of that Body Fat Ratio on the efficacy of different lipid soluble anesthetics.

Interventions

DRUGSufentanil (R30730, brand name Sufenta)

sufentanil 1ug/ml

DRUGSufentanil (R30730, brand name Sufenta) + Morphine

sufentanil 0.5ug/ml+morphine 0.25mg/ml

DRUGMorphine

morphine 0. 5mg/ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists grade I-II * adults aged over 20 and below 50 years old, * non-smoker, * with normal hepatic and renal function.

Exclusion criteria

* smoker , * any kind of mental disorder or * history use of analgesics for more than 10 consecutive days, * asthma; and * those with digestion tract disorder who would get nausea or vomiting much more easily than normal people.

Design outcomes

Primary

Measure	Time frame	Description
visual analogue pain scores	24hour	we evaluate visual analogue pain scores at different time points within 24 hours after surgery

Secondary

Measure	Time frame	Description
nausea & vomiting	24hour	we evaluate nausea & vomiting at different time points within 24 hours after surgery. we ask the patient if she feel nausea or/and occured vomit, if so, 1 time will be recorded in the time point for incidence.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026